270520 — APT Neuroscience Balance Sheet
0.000.00%
- KR₩183bn
- KR₩99bn
- KR₩18bn
Annual balance sheet for APT Neuroscience, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 14,478 | 18,850 | 50,489 | 66,678 | 182,758 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 15,705 | 11,624 | 5,833 | 7,308 | 6,564 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 30,279 | 30,802 | 58,797 | 74,440 | 190,856 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,243 | 1,177 | 1,414 | 4,801 | 4,783 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 35,783 | 36,255 | 66,139 | 98,563 | 206,415 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5,445 | 6,791 | 23,652 | 39,809 | 125,180 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 5,572 | 6,930 | 23,777 | 40,137 | 125,492 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 30,211 | 29,325 | 42,362 | 58,426 | 80,922 |
Total Liabilities & Shareholders' Equity | 35,783 | 36,255 | 66,139 | 98,563 | 206,415 |
Total Common Shares Outstanding |